Study · Randomized controlled trial · 2009

13 results

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).

Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S

Diabetic medicine : a journal of the British Diabetic Association1 Mar 2009Cited by 610 (Europe PMC)

PMID19317822PMCIDPMC2871176DOI10.1111/j.1464-5491.2009.02666.xPepBankPUB-19317822

Summary

AimTo compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n >or= 228) or placebo (n = 114) with glimepiride (2-4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes.MethodsIn total, 1041 adults (mean +/- sd), age 56 +/- 10 years, weight 82 +/- 17 kg and glycated haemoglobin (HbA(1c)) 8.4 +/- 1.0% at 116 sites in 21 countries were stratified based on previous oral glucose-lowering mono : combination therapies (30 : 70%) to participate in a five-arm, 26-week, double-dummy, randomized study.ResultsLiraglutide (1.2 or 1.8 mg) produced greater reductions in HbA(1c) from baseline, (-1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%) or rosiglitazone (-0.4%, P < 0.0001, baseline 8.4%) when added to glimepiride. Liraglutide 0.6 mg was less effective (-0.6%, baseline 8.4%). Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l). Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [-2.5 to -2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (-0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (-1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l). Changes in body weight with liraglutide 1.8 mg (-0.2 kg, baseline 83.0 kg), 1.2 mg (+0.3 kg, baseline 80.0 kg) or placebo (-0.1 kg, baseline 81.9 kg) were less than with rosiglitazone (+2.1 kg, P < 0.0001, baseline 80.6 kg). Main adverse events for all treatments were minor hypoglycaemia (< 10%), nausea (< 11%), vomiting (< 5%) and diarrhoea (< 8%).ConclusionsLiraglutide added to glimepiride was well tolerated and provided improved glycaemic control and favourable weight profile.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study13

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on glimepiride, liraglutide 1.2 or 1.8 mg reduced HbA1c by 1.1% from baseline, versus a 0.2% rise with placebo.
In plain wordsIn adults with type 2 diabetes, liraglutide added to glimepiride lowered HbA1c more than placebo did.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change from baseline
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 or 1.8 mg/day · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−1.1%
liraglutide 1.2 or 1.8 mg
HbA1c change
0.2%
placebo
Source sentences
Summary
Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA(1c) from baseline, (-1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%) or rosiglitazone (-0.4%, P < 0.0001, baseline 8.4%) when added to glimepiride.
2 context sentences(design, population, supporting numbers)
Summary · context
To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n >or= 228) or placebo (n = 114) with glimepiride (2-4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes.
Summary · context
In total, 1041 adults (mean +/- sd), age 56 +/- 10 years, weight 82 +/- 17 kg and glycated haemoglobin (HbA(1c)) 8.4 +/- 1.0% at 116 sites in 21 countries were stratified based on previous oral glucose-lowering mono : combination therapies (30 : 70%) to participate in a five-arm, 26-week, double-dummy, randomized study.
Show in the study text Report a problemFND-1931782201
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on glimepiride, liraglutide 1.2 or 1.8 mg reduced HbA1c by 1.1% versus 0.4% with rosiglitazone.
In plain wordsIn adults with type 2 diabetes, liraglutide added to glimepiride lowered HbA1c more than rosiglitazone did.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change from baseline
Study
n: not reported in source
Comparator
Rosiglitazone 4 mg/day
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 or 1.8 mg/day · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−1.1%
liraglutide 1.2 or 1.8 mg
HbA1c change
−0.4%
rosiglitazone
Source sentences
Summary
Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA(1c) from baseline, (-1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%) or rosiglitazone (-0.4%, P < 0.0001, baseline 8.4%) when added to glimepiride.
2 context sentences(design, population, supporting numbers)
Summary · context
To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n >or= 228) or placebo (n = 114) with glimepiride (2-4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes.
Summary · context
In total, 1041 adults (mean +/- sd), age 56 +/- 10 years, weight 82 +/- 17 kg and glycated haemoglobin (HbA(1c)) 8.4 +/- 1.0% at 116 sites in 21 countries were stratified based on previous oral glucose-lowering mono : combination therapies (30 : 70%) to participate in a five-arm, 26-week, double-dummy, randomized study.
Show in the study text Report a problemFND-1931782202
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on glimepiride, liraglutide 0.6 mg reduced HbA1c by 0.6%, which was less effective than the higher doses.
In plain wordsIn adults with type 2 diabetes, the lowest liraglutide dose lowered HbA1c, but less than the higher doses.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change from baseline
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 mg/day · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−0.6%
liraglutide 0.6 mg
Source sentences
Summary
Liraglutide 0.6 mg was less effective (-0.6%, baseline 8.4%).
2 context sentences(design, population, supporting numbers)
Summary · context
To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n >or= 228) or placebo (n = 114) with glimepiride (2-4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes.
Summary · context
In total, 1041 adults (mean +/- sd), age 56 +/- 10 years, weight 82 +/- 17 kg and glycated haemoglobin (HbA(1c)) 8.4 +/- 1.0% at 116 sites in 21 countries were stratified based on previous oral glucose-lowering mono : combination therapies (30 : 70%) to participate in a five-arm, 26-week, double-dummy, randomized study.
Show in the study text Report a problemFND-1931782203
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on glimepiride, liraglutide 1.2 or 1.8 mg lowered fasting plasma glucose by 1.6 mmol/l, versus a 0.9 mmol/l increase with placebo.
In plain wordsIn adults with type 2 diabetes, liraglutide lowered fasting blood glucose while it rose with placebo.
Peptide
Liraglutide
Outcome
DecreaseFasting plasma glucose change
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 or 1.8 mg/day · 26 weeksAs given in this study (human).
Measurements
fasting plasma glucose change
−1.6 mmol/l
liraglutide 1.2 or 1.8 mg
fasting plasma glucose change
0.9 mmol/l
placebo
Source sentences
Summary
Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).
2 context sentences(design, population, supporting numbers)
Summary · context
To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n >or= 228) or placebo (n = 114) with glimepiride (2-4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes.
Summary · context
In total, 1041 adults (mean +/- sd), age 56 +/- 10 years, weight 82 +/- 17 kg and glycated haemoglobin (HbA(1c)) 8.4 +/- 1.0% at 116 sites in 21 countries were stratified based on previous oral glucose-lowering mono : combination therapies (30 : 70%) to participate in a five-arm, 26-week, double-dummy, randomized study.
Show in the study text Report a problemFND-1931782204
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on glimepiride, liraglutide 1.2 or 1.8 mg lowered fasting plasma glucose by 1.6 mmol/l versus 1.0 mmol/l with rosiglitazone.
In plain wordsIn adults with type 2 diabetes, liraglutide lowered fasting blood glucose more than rosiglitazone did.
Peptide
Liraglutide
Outcome
DecreaseFasting plasma glucose change
Study
n: not reported in source
Comparator
Rosiglitazone 4 mg/day
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 or 1.8 mg/day · 26 weeksAs given in this study (human).
Measurements
fasting plasma glucose change
−1.6 mmol/l
liraglutide 1.2 or 1.8 mg
fasting plasma glucose change
−1 mmol/l
rosiglitazone
Source sentences
Summary
Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).
2 context sentences(design, population, supporting numbers)
Summary · context
To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n >or= 228) or placebo (n = 114) with glimepiride (2-4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes.
Summary · context
In total, 1041 adults (mean +/- sd), age 56 +/- 10 years, weight 82 +/- 17 kg and glycated haemoglobin (HbA(1c)) 8.4 +/- 1.0% at 116 sites in 21 countries were stratified based on previous oral glucose-lowering mono : combination therapies (30 : 70%) to participate in a five-arm, 26-week, double-dummy, randomized study.
Show in the study text Report a problemFND-1931782205
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on glimepiride, liraglutide 1.2 or 1.8 mg lowered postprandial plasma glucose more than placebo (-0.4 mmol/l).
In plain wordsIn adults with type 2 diabetes, liraglutide lowered blood glucose after meals more than placebo did.
Peptide
Liraglutide
Outcome
DecreasePostprandial plasma glucose change
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 or 1.8 mg/day · 26 weeksAs given in this study (human).
Measurements
postprandial glucose change
−2.5 mmol/l
liraglutide 1.2 or 1.8 mg, lower bound of range
postprandial glucose change
−2.7 mmol/l
liraglutide 1.2 or 1.8 mg, upper bound of range
postprandial glucose change
−0.4 mmol/l
placebo
Source sentences
Summary
Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [-2.5 to -2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (-0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (-1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l).
2 context sentences(design, population, supporting numbers)
Summary · context
To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n >or= 228) or placebo (n = 114) with glimepiride (2-4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes.
Summary · context
In total, 1041 adults (mean +/- sd), age 56 +/- 10 years, weight 82 +/- 17 kg and glycated haemoglobin (HbA(1c)) 8.4 +/- 1.0% at 116 sites in 21 countries were stratified based on previous oral glucose-lowering mono : combination therapies (30 : 70%) to participate in a five-arm, 26-week, double-dummy, randomized study.
Show in the study text Report a problemFND-1931782206
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on glimepiride, liraglutide 1.2 or 1.8 mg lowered postprandial plasma glucose more than rosiglitazone (-1.8 mmol/l).
In plain wordsIn adults with type 2 diabetes, liraglutide lowered blood glucose after meals more than rosiglitazone did.
Peptide
Liraglutide
Outcome
DecreasePostprandial plasma glucose change
Study
n: not reported in source
Comparator
Rosiglitazone 4 mg/day
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 or 1.8 mg/day · 26 weeksAs given in this study (human).
Measurements
postprandial glucose change
−1.8 mmol/l
rosiglitazone
Source sentences
Summary
Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [-2.5 to -2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (-0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (-1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l).
2 context sentences(design, population, supporting numbers)
Summary · context
To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n >or= 228) or placebo (n = 114) with glimepiride (2-4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes.
Summary · context
In total, 1041 adults (mean +/- sd), age 56 +/- 10 years, weight 82 +/- 17 kg and glycated haemoglobin (HbA(1c)) 8.4 +/- 1.0% at 116 sites in 21 countries were stratified based on previous oral glucose-lowering mono : combination therapies (30 : 70%) to participate in a five-arm, 26-week, double-dummy, randomized study.
Show in the study text Report a problemFND-1931782207
08HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on glimepiride, body weight changed by -0.2 kg with liraglutide 1.8 mg, less than the 2.1 kg gain with rosiglitazone.
In plain wordsIn adults with type 2 diabetes, weight with liraglutide 1.8 mg stayed stable, while it rose with rosiglitazone.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n: not reported in source
Comparator
Rosiglitazone 4 mg/day
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg/day · 26 weeksAs given in this study (human).
Measurements
body weight change
−0.2 kg
liraglutide 1.8 mg
body weight change
2.1 kg
rosiglitazone
Source sentences
Summary
Changes in body weight with liraglutide 1.8 mg (-0.2 kg, baseline 83.0 kg), 1.2 mg (+0.3 kg, baseline 80.0 kg) or placebo (-0.1 kg, baseline 81.9 kg) were less than with rosiglitazone (+2.1 kg, P < 0.0001, baseline 80.6 kg).
2 context sentences(design, population, supporting numbers)
Summary · context
To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n >or= 228) or placebo (n = 114) with glimepiride (2-4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes.
Summary · context
In total, 1041 adults (mean +/- sd), age 56 +/- 10 years, weight 82 +/- 17 kg and glycated haemoglobin (HbA(1c)) 8.4 +/- 1.0% at 116 sites in 21 countries were stratified based on previous oral glucose-lowering mono : combination therapies (30 : 70%) to participate in a five-arm, 26-week, double-dummy, randomized study.
Show in the study text Report a problemFND-1931782208
09HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on glimepiride, body weight changed by +0.3 kg with liraglutide 1.2 mg, less than the 2.1 kg gain with rosiglitazone.
In plain wordsIn adults with type 2 diabetes, weight rose less with liraglutide 1.2 mg than with rosiglitazone.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n: not reported in source
Comparator
Rosiglitazone 4 mg/day
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg/day · 26 weeksAs given in this study (human).
Measurements
body weight change
0.3 kg
liraglutide 1.2 mg
body weight change
2.1 kg
rosiglitazone
Source sentences
Summary
Changes in body weight with liraglutide 1.8 mg (-0.2 kg, baseline 83.0 kg), 1.2 mg (+0.3 kg, baseline 80.0 kg) or placebo (-0.1 kg, baseline 81.9 kg) were less than with rosiglitazone (+2.1 kg, P < 0.0001, baseline 80.6 kg).
2 context sentences(design, population, supporting numbers)
Summary · context
To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n >or= 228) or placebo (n = 114) with glimepiride (2-4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes.
Summary · context
In total, 1041 adults (mean +/- sd), age 56 +/- 10 years, weight 82 +/- 17 kg and glycated haemoglobin (HbA(1c)) 8.4 +/- 1.0% at 116 sites in 21 countries were stratified based on previous oral glucose-lowering mono : combination therapies (30 : 70%) to participate in a five-arm, 26-week, double-dummy, randomized study.
Show in the study text Report a problemFND-1931782209

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

10HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome
In adults with type 2 diabetes on glimepiride, minor hypoglycaemia occurred in under 10% of patients across all treatments.
In plain wordsIn adults with type 2 diabetes, minor low blood sugar was reported in fewer than 10% of patients across all treatments.
Peptide
Liraglutide
Outcome
Not applicableMinor hypoglycaemia
Study
n = 1,041
Outcome group
Adverse events · Metabolic and weight
Measurements
minor hypoglycaemia
< 10%
all treatments
Source sentences
Summary
Main adverse events for all treatments were minor hypoglycaemia (< 10%), nausea (< 11%), vomiting (< 5%) and diarrhoea (< 8%).
2 context sentences(design, population, supporting numbers)
Summary · context
To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n >or= 228) or placebo (n = 114) with glimepiride (2-4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes.
Summary · context
In total, 1041 adults (mean +/- sd), age 56 +/- 10 years, weight 82 +/- 17 kg and glycated haemoglobin (HbA(1c)) 8.4 +/- 1.0% at 116 sites in 21 countries were stratified based on previous oral glucose-lowering mono : combination therapies (30 : 70%) to participate in a five-arm, 26-week, double-dummy, randomized study.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-1931782210
11HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome
In adults with type 2 diabetes on glimepiride, nausea occurred in under 11% of patients across all treatments.
In plain wordsIn adults with type 2 diabetes, nausea was reported in fewer than 11% of patients across all treatments.
Peptide
Liraglutide
Outcome
Not applicableNausea
Study
n = 1,041
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
nausea
< 11%
all treatments
Source sentences
Summary
Main adverse events for all treatments were minor hypoglycaemia (< 10%), nausea (< 11%), vomiting (< 5%) and diarrhoea (< 8%).
2 context sentences(design, population, supporting numbers)
Summary · context
To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n >or= 228) or placebo (n = 114) with glimepiride (2-4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes.
Summary · context
In total, 1041 adults (mean +/- sd), age 56 +/- 10 years, weight 82 +/- 17 kg and glycated haemoglobin (HbA(1c)) 8.4 +/- 1.0% at 116 sites in 21 countries were stratified based on previous oral glucose-lowering mono : combination therapies (30 : 70%) to participate in a five-arm, 26-week, double-dummy, randomized study.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-1931782211
12HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome
In adults with type 2 diabetes on glimepiride, vomiting occurred in under 5% of patients across all treatments.
In plain wordsIn adults with type 2 diabetes, vomiting was reported in fewer than 5% of patients across all treatments.
Peptide
Liraglutide
Outcome
Not applicableVomiting
Study
n = 1,041
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
vomiting
< 5%
all treatments
Source sentences
Summary
Main adverse events for all treatments were minor hypoglycaemia (< 10%), nausea (< 11%), vomiting (< 5%) and diarrhoea (< 8%).
2 context sentences(design, population, supporting numbers)
Summary · context
To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n >or= 228) or placebo (n = 114) with glimepiride (2-4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes.
Summary · context
In total, 1041 adults (mean +/- sd), age 56 +/- 10 years, weight 82 +/- 17 kg and glycated haemoglobin (HbA(1c)) 8.4 +/- 1.0% at 116 sites in 21 countries were stratified based on previous oral glucose-lowering mono : combination therapies (30 : 70%) to participate in a five-arm, 26-week, double-dummy, randomized study.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-1931782212
13HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome
In adults with type 2 diabetes on glimepiride, diarrhoea occurred in under 8% of patients across all treatments.
In plain wordsIn adults with type 2 diabetes, diarrhoea was reported in fewer than 8% of patients across all treatments.
Peptide
Liraglutide
Outcome
Not applicableDiarrhoea
Study
n = 1,041
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
diarrhoea
< 8%
all treatments
Source sentences
Summary
Main adverse events for all treatments were minor hypoglycaemia (< 10%), nausea (< 11%), vomiting (< 5%) and diarrhoea (< 8%).
2 context sentences(design, population, supporting numbers)
Summary · context
To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n >or= 228) or placebo (n = 114) with glimepiride (2-4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes.
Summary · context
In total, 1041 adults (mean +/- sd), age 56 +/- 10 years, weight 82 +/- 17 kg and glycated haemoglobin (HbA(1c)) 8.4 +/- 1.0% at 116 sites in 21 countries were stratified based on previous oral glucose-lowering mono : combination therapies (30 : 70%) to participate in a five-arm, 26-week, double-dummy, randomized study.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-1931782213

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials3

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

3 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 3NCT03421119

Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes

Cinnagenn = 300est. 20 Jun 2019 to est. 1 Dec 2019

Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 6 Feb 2019

CompletedPhase 4NCT01761318

Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients

Leiden University Medical Centern = 50Nov 2013 to Mar 2016

Diabetes Mellitus Type 2 · Metabolic Syndrome · Cardiovascular Disease · Diastolic Dysfunction · Fatty Liver

Trial page ClinicalTrials.govUpdated 5 May 2016

CompletedPhase 3NCT00318422

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 1,041May 2006 to May 2007

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 25 Jan 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.